14 results about "Solid oral dosage form" patented technology

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention relates to the pharmaceutical compositions comprising nor-UDCA or pharmaceutically acceptable salt or ester thereof and the process for preparation. The present invention most preferably discloses the solid oral dosage form of nor-UDCA preferably in the form of tablets, capsules, disintegrating tablets and effervescent tablets.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

This invention relates to novel pharmaceutical formulations, including solid oral dosage forms containing the non-psychoactive cannabidiol (CBD). The invention also relates to methods for preparing the pharmaceutical formulation and its application in treating diseases and conditions.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention discloses high-purity oral solid dosage forms comprising sacubitril, valsartan, its complex or pharmaceutically acceptable salts thereof, and an SGLT-2 inhibitor or pharmaceutically acceptable salts thereof, together with one or more pharmaceutically acceptable excipients, wherein the active ingredients are in a single-compartment form, without physical separation between them, distributed uniformly and homogeneously.

This disclosure discloses a core-shell encapsulated medium-chain fatty acid salt, wherein (i) the core comprises at least one of an alkali metal salt of a medium-chain fatty acid or a saprolizumab-functionalized medium-chain fatty acid salt; and (ii) the shell comprises at least one of an alkali metal salt of a medium-chain fatty acid encapsulating the core or a saprolizumab-functionalized medium-chain fatty acid salt. The use of such encapsulated acid in pharmaceutical compositions is also disclosed, particularly in oral solid dosage forms such as tablets. The tablets of this disclosure exhibit excellent mechanical properties.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

An orally swallowable, immediate release tablet, comprising itopride or a pharmaceutically acceptable salt thereof as an active ingredient, characterized in that the tablet comprises granules containing the active ingredient, mannitol and optionally at least one additional pharmaceutically acceptable excipient, wherein the tablet does not contain lactose. Said tablet for use in prevention or treatment of gastrointestinal motility disorders. A method for manufacturing the orally swallowable, immediate release tablet according to any of the preceding claims, comprising: a) granulating itopride or a pharmaceutically acceptable salt thereof with mannitol and optionally at least one additional pharmaceutically acceptable excipient, b) optionally blending the granules obtained in step a) with at least one extra-granular pharmaceutically acceptable excipient, and c) compressing the granules from step a) or the blend from step b) into tablets.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.